Abstract P1038: Blood Metabolomic Signatures of Incident Coronary Heart Disease in Racially and Ethnically Diverse Populations
Abstract
Background: Metabolic perturbation has been characterized in coronary heart disease (CHD), yet the comprehensive metabolic fingerprint of incident CHD and potential racial/ethnical differences remain unclear. Hypothesis: Circulating metabolite alterations are associated with CHD risk, but associations vary across race/ethnicity. Methods: We included 22,566 CHD-free individuals of multi-ethnic groups from 7 studies in the Trans-Omics for Precision Medicine Program ( Fig.a ). Associations between metabolites (1245 named metabolites) and incident CHD were assessed by study/race-specific Cox proportional hazards regression. Results were pooled via random-effect meta-analyses. Results: Over an average of 7.5~17.0 yrs of follow-up 1124 incident CHD cases were recorded. We found that 280 metabolites were associated with incident CHD after adjusting for sociodemographic, behavioral factors, medications use, physical activity, and diet (FDR < 0.05), with over 64% were independent of other major cardiometabolic traits ( Fig.b ). Over 90% of these metabolites showed positive associations, with strongest associations in metabolites of glycerolipids, phosphatidylethanolamine, fatty acids, lactoyl amino acid, histidine, aromatic amino acids, and branched amino acids ( Fig.b ). Race-specific analyses identified 70 metabolites presenting significant race/ethnicity differences (FDR<0.05) in associations with CHD, with 34 being race/ethnicity specific metabolites that were not found in all participants (16 in Blacks, 11 in Whites and 7 in Hispanics; Fig.c-e ). For example, guanidinosuccinate, a known uremic toxin, was associated with increased risk of CHD only in US Hispanics, reinforcing the chronic kidney disease (CKD)-cardiovascular diseases continuum, especially for populations at high risk of CKD. Conclusion: Our study characterized the most comprehensive metabolic signatures of incident CHD and revealed substantial racial differences, further emphasizing the need of multi-ethnic resources to uncover metabolic perturbation underlying CHD.
Article Details
Authors (25)
Kai Luo
Taryn Alkis
The University of Texas Health Science Center at Houston, Houston, Texas, United States
Eun Hye Moon
UTHealth at Houston, Houston, Texas, United States
Christie Ballantyne
BAYLOR COLLEGE MEDICINE, Houston, Texas, United States
Eric Boerwinkle
Clary Clish
Robert Gerszten
Megan Grove
UTHealth, Houston, Texas, United States
Lifang Hou
Scott Hutton
Metabolon, Inc, Morrisville, North Carolina, United States
Robert Kaplan
Rozenn Lemaitre
Cardiovascular Health Research Unit, Department of Medicine University of Washington, Seattle, Washington, United States
Donald Lloyd-Jones
Framingham Center for Population and Prevention Science, Framingham, MA
Matthew Nayor
Kari North
UNIV OF TX HEALTH SCI CTR HOUSTON, Houston, Texas, United States
Bruce Psaty
University of Washington, Seattle, WA, USA.
Laura Raffield
Stephen Rich
Jerome Rotter
The Lundquist Institute, Torrance, California, United States
Usman Tahir
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Tao Wang
Kari Wong
Vanessa Xanthakis
Qibin Qi
Bing Yu
College of Chemistry and Materials Science, Guangdong Provincial Key Laboratory of Supramolecular Coordination Chemistry